Trial Profile
A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Graves ophthalmopathy
- Focus Pharmacodynamics
- Sponsors Ipsen
- 07 Apr 2022 This trial has been completed in Spain (Global end date: 27/10/2006), according to European Clinical Trials Database record.
- 07 Oct 2015 New trial record